Royal Bank of Canada
ARQT icon

Royal Bank of Canada’s Arcutis Biotherapeutics ARQT Stock Holding History

Royal Bank of Canada’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32K Sell
1,383
-3,602
-72% -$91.9K ﹤0.01% 5687
2025
Q4 		$145K Sell
4,985
-183,295
-97% -$4.69M ﹤0.01% 4981
2025
Q3 		$3.55M Sell
188,280
-75,529
-29% -$1.19M ﹤0.01% 2933
2025
Q2 		$3.7M Buy
263,809
+259,142
+5,553% +$3.63M ﹤0.01% 2817
2025
Q1 		$73K Buy
4,667
+1,828
+64% +$25.8K ﹤0.01% 5391
2024
Q4 		$40K Sell
2,839
-9,407
-77% -$103K ﹤0.01% 5789
2024
Q3 		$113K Sell
12,246
-407
-3% -$4.02K ﹤0.01% 5256
2024
Q2 		$118K Buy
12,653
+9,558
+309% +$86.4K ﹤0.01% 5161
2024
Q1 		$31K Sell
3,095
-17,999
-85% -$134K ﹤0.01% 5722
2023
Q4 		$68K Buy
21,094
+13,616
+182% +$37K ﹤0.01% 5837
2023
Q3 		$39K Buy
7,478
+3,006
+67% +$25.6K ﹤0.01% 5902
2023
Q2 		$42K Buy
4,472
+1,118
+33% +$12.4K ﹤0.01% 5849
2023
Q1 		$37K Sell
3,354
-3,124
-48% -$45.2K ﹤0.01% 5771
2022
Q4 		$96K Buy
6,478
+5,349
+474% +$93.5K ﹤0.01% 5478
2022
Q3 		$21K Buy
1,129
+477
+73% +$10.8K ﹤0.01% 6110
2022
Q2 		$14K Sell
652
-1,248
-66% -$25.6K ﹤0.01% 6234
2022
Q1 		$37K Sell
1,900
-3,207
-63% -$54.3K ﹤0.01% 6268
2021
Q4 		$106K Buy
5,107
+2,467
+93% +$49.1K ﹤0.01% 5884
2021
Q3 		$63K Buy
2,640
+587
+29% +$13.4K ﹤0.01% 6015
2021
Q2 		$56K Buy
2,053
+768
+60% +$21.6K ﹤0.01% 5951
2021
Q1 		$37K Buy
1,285
+962
+298% +$30K ﹤0.01% 6065
2020
Q4 		$9K Buy
323
+304
+1,600% +$7.45K ﹤0.01% 6409
2020
Q3 		$1K Buy
19
+2
+12% +$53 ﹤0.01% 6386
2020
Q2 		$1K Sell
17
-540
-97% -$15.6K ﹤0.01% 6378
2020
Q1 		$16K Buy
+557
New +$15K ﹤0.01% 5626

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada's ARQT Position: Q1 2026 in Review

Royal Bank of Canada reduced its Arcutis Biotherapeutics (ARQT) stake by 72% in Q1 2026, selling an estimated $91.9K and leaving 1,383 shares worth $32K. The position accounts for ﹤0.01% of the portfolio, ranked #5687.

Royal Bank of Canada first reported a position in ARQT in Q1 2020 and has held it in 25 quarters since. The position peaked at $3.7M in Q2 2025. 270 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Royal Bank of Canada held 1,383 shares of Arcutis Biotherapeutics worth $32K as of Q1 2026.
  • Royal Bank of Canada sold 3,602 Arcutis Biotherapeutics shares in Q1 2026, an estimated $91.9K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5687 holding.
  • Royal Bank of Canada first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 25 quarters since.
  • Royal Bank of Canada's Arcutis Biotherapeutics position peaked at $3.7M in Q2 2025.
  • 270 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.